SOCS2 Antibody (Rabbit mAb) [H21H24]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:10000 IP1:10 - 1:100 IF1:100 - 1:250 FCM1:150

Application
WB, IP, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
22 kDa 22 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
SOCS2 Antibody (Rabbit mAb) [H21H24] detects endogenous levels of total SOCS2 protein.

Clone
H21H24

Synonym(s)
CIS2, SSI2, STATI2, SOCS2, Suppressor of cytokine signaling 2, SOCS-2, Cytokine-inducible SH2 protein 2, STAT-induced STAT inhibitor 2, CIS-2, SSI-2

Background
SOCS2 is a cytokine‑inducible member of the suppressor of cytokine signaling family that functions as the substrate‑recognition subunit of a Cullin‑5–RING E3 ubiquitin ligase (ECS/CRL5) complex, where it negatively regulates JAK–STAT signaling by targeting activated cytokine and growth hormone receptors for ubiquitin‑dependent degradation. The protein contains a central SH2 domain that binds phosphotyrosine motifs on ligand‑activated receptors or associated kinases, and a C‑terminal SOCS box that recruits Elongin B/C, Cullin‑5 and Rbx2 to assemble a functional ubiquitin ligase, establishing a modular architecture that couples phospho‑dependent substrate recognition to proteasomal turnover. In growth hormone signaling, SOCS2 is strongly induced by GH and docks via its SH2 domain onto phosphorylated tyrosines within the intracellular tail of the growth hormone receptor after JAK2 activation; the assembled ECS(SOCS2) complex ubiquitinates GHR and promotes its internalization and degradation, forming a feedback loop that limits receptor abundance, constrains downstream STAT5 activation and shapes IGF‑1–related somatic growth. SOCS2 similarly recognizes JAK2‑phosphorylated erythropoietin receptor and catalyzes its ubiquitination and proteasomal degradation, attenuating erythropoietin‑induced JAK–STAT signaling and contributing to control of erythroid proliferation and survival. Structural work on SOCS2–elongin C–elongin B complexes shows how the SH2 domain and SOCS box are positioned to accommodate phosphopeptide substrates while maintaining stable association with the Elongin BC–Cullin‑5 module, clarifying how substrate binding and ligase assembly are integrated into a single compact scaffold that guides CRL5 specificity. Beyond GH and EPO pathways, SOCS2 binds IGF‑1 receptor and other cytokine receptors, and review data indicate that SOCS2 modulates multiple JAK–STAT‑dependent networks in metabolism, central nervous system function, immune responses and mammary gland biology, so SOCS2 levels and activity influence diverse physiological processes through control of receptor density and signaling intensity. Dysregulation of SOCS2—through loss‑of‑function mutations, altered expression or perturbed post‑translational modification, has been linked to abnormal somatic growth via enhanced GH/IGF‑1 signaling, heightened inflammatory responses of macrophages to Toll‑like receptor ligands, and associations with cancer, insulin resistance and cardiovascular disease, consistent with its role as a central brake on cytokine and growth factor signaling.

Background

SOCS2 is a cytokine‑inducible member of the suppressor of cytokine signaling family that functions as the substrate‑recognition subunit of a Cullin‑5–RING E3 ubiquitin ligase (ECS/CRL5) complex, where it negatively regulates JAK–STAT signaling by targeting activated cytokine and growth hormone receptors for ubiquitin‑dependent degradation. The protein contains a central SH2 domain that binds phosphotyrosine motifs on ligand‑activated receptors or associated kinases, and a C‑terminal SOCS box that recruits Elongin B/C, Cullin‑5 and Rbx2 to assemble a functional ubiquitin ligase, establishing a modular architecture that couples phospho‑dependent substrate recognition to proteasomal turnover. In growth hormone signaling, SOCS2 is strongly induced by GH and docks via its SH2 domain onto phosphorylated tyrosines within the intracellular tail of the growth hormone receptor after JAK2 activation; the assembled ECS(SOCS2) complex ubiquitinates GHR and promotes its internalization and degradation, forming a feedback loop that limits receptor abundance, constrains downstream STAT5 activation and shapes IGF‑1–related somatic growth. SOCS2 similarly recognizes JAK2‑phosphorylated erythropoietin receptor and catalyzes its ubiquitination and proteasomal degradation, attenuating erythropoietin‑induced JAK–STAT signaling and contributing to control of erythroid proliferation and survival. Structural work on SOCS2–elongin C–elongin B complexes shows how the SH2 domain and SOCS box are positioned to accommodate phosphopeptide substrates while maintaining stable association with the Elongin BC–Cullin‑5 module, clarifying how substrate binding and ligase assembly are integrated into a single compact scaffold that guides CRL5 specificity. Beyond GH and EPO pathways, SOCS2 binds IGF‑1 receptor and other cytokine receptors, and review data indicate that SOCS2 modulates multiple JAK–STAT‑dependent networks in metabolism, central nervous system function, immune responses and mammary gland biology, so SOCS2 levels and activity influence diverse physiological processes through control of receptor density and signaling intensity. Dysregulation of SOCS2—through loss‑of‑function mutations, altered expression or perturbed post‑translational modification, has been linked to abnormal somatic growth via enhanced GH/IGF‑1 signaling, heightened inflammatory responses of macrophages to Toll‑like receptor ligands, and associations with cancer, insulin resistance and cardiovascular disease, consistent with its role as a central brake on cytokine and growth factor signaling.

References
https://pubmed.ncbi.nlm.nih.gov/21980433/ https://pubmed.ncbi.nlm.nih.gov/26709655/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%